Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Department of Quantitative Health Sciences, Division of Clinical Trials & Biostatistics, Mayo Clinic, Rochester, MN, USA.
Neuroimage Clin. 2023;40:103507. doi: 10.1016/j.nicl.2023.103507. Epub 2023 Sep 9.
Brain imaging research studies increasingly use "de-facing" software to remove or replace facial imagery before public data sharing. Several works have studied the effects of de-facing software on brain imaging biomarkers by directly comparing automated measurements from unmodified vs de-faced images, but most research brain images are used in analyses of correlations with cognitive measurements or clinical statuses, and the effects of de-facing on these types of imaging-to-cognition correlations has not been measured. In this work, we focused on brain imaging measures of amyloid (A), tau (T), neurodegeneration (N), and vascular (V) measures used in Alzheimer's Disease (AD) research. We created a retrospective sample of participants from three age- and sex-matched clinical groups (cognitively unimpaired, mild cognitive impairment, and AD dementia, and we performed region- and voxel-wise analyses of: hippocampal volume (N), white matter hyperintensity volume (V), amyloid PET (A), and tau PET (T) measures, each from multiple software pipelines, on their ability to separate cognitively defined groups and their degrees of correlation with age and Clinical Dementia Rating (CDR)-Sum of Boxes (CDR-SB). We performed each of these analyses twice: once with unmodified images and once with images de-faced with leading de-facing software mri_reface, and we directly compared the findings and their statistical strengths between the original vs. the de-faced images. Analyses with original and with de-faced images had very high agreement. There were no significant differences between any voxel-wise comparisons. Among region-wise comparisons, only three out of 55 correlations were significantly different between original and de-faced images, and these were not significant after correction for multiple comparisons. Overall, the statistical power of the imaging data for AD biomarkers was almost identical between unmodified and de-faced images, and their analyses results were extremely consistent.
脑成像研究越来越多地使用“去脸”软件,在公共数据共享之前去除或替换面部图像。有几项研究通过直接比较未经修改和去脸图像的自动测量值来研究去脸软件对脑成像生物标志物的影响,但大多数研究脑图像用于分析与认知测量或临床状态的相关性,并且去脸对这些类型的成像与认知相关性的影响尚未测量。在这项工作中,我们专注于阿尔茨海默病(AD)研究中使用的淀粉样蛋白(A)、tau(T)、神经退行性变(N)和血管(V)的脑成像测量值。我们创建了一个回顾性样本,包括来自三个年龄和性别匹配的临床组(认知未受损、轻度认知障碍和 AD 痴呆)的参与者,我们对每个参与者进行了海马体积(N)、脑白质高信号体积(V)、淀粉样蛋白 PET(A)和 tau PET(T)的区域和体素分析,这些分析来自多个软件管道,以分离认知定义的组,并分析它们与年龄和临床痴呆评定量表总和分(CDR-SB)的相关性。我们对这些分析进行了两次:一次是对未经修改的图像进行分析,一次是对使用领先的去脸软件 mri_reface 进行去脸的图像进行分析,并直接比较原始图像和去脸图像的结果及其统计强度。原始图像和去脸图像的分析具有非常高的一致性。在任何体素比较中都没有发现显著差异。在区域比较中,只有 55 个相关性中的三个在原始图像和去脸图像之间存在显著差异,并且在进行多次比较校正后这些差异不再显著。总体而言,AD 生物标志物的成像数据的统计效力在未经修改和去脸的图像之间几乎相同,并且它们的分析结果非常一致。